# Progress Note 01 — Initial plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Barbara Jordan (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML030-SYN
- Date: 2026-03-02
- Fictional facility: St. Posthumous Health Center
- Fictional author: Evangeline Moss, MD
- Calendar frame: modern shifted

## Subjective

The patient participates in this fictional visit for establishing primary care for multiple sclerosis diagnosed elsewhere: walking, spasticity, bladder, fatigue and heat sensitivity, work, bone health, mood, and the work-up and screening before any disease-modifying therapy. **S**

## Objective

White cells: 6.4 10*3/uL; Lymphocytes (absolute): 1.9 10*3/uL; Hemoglobin: 13.2 g/dL; Platelets: 262 10*3/uL; Creatinine: 0.78 mg/dL; eGFR (CKD-EPI 2021): 96 mL/min/1.73 m²; ALT: 18 U/L; AST: 20 U/L; Alkaline phosphatase: 72 U/L; Total bilirubin: 0.5 mg/dL; TSH: 1.8 mIU/L; Vitamin B12: 520 pg/mL; 25-hydroxyvitamin D: 17 ng/mL (low); IgG: 1080 mg/dL; IgM: 110 mg/dL; IgA: 210 mg/dL; JC virus antibody index: 0.14; PHQ-9: 6. All results are synthetic.

BP 124/78 mmHg; pulse 76 bpm; respirations 16/min; temperature 36.7 °C; oxygen saturation 98% on room air; weight 84 kg; BMI 28.1 kg/m². All vital signs are synthetic.

## Assessment

Active problems: Multiple sclerosis diagnosed elsewhere, by her account, with records of the original evaluation not available: slowly worsening walking over the past few years, leg stiffness, fatigue, urinary urgency and heat sensitivity; uses a cane; course to be classified after MRI of the brain and spine; Spastic gait from multiple sclerosis, walking with a cane, with two near-falls and no falls in the past year; at risk of falls; Neurogenic bladder from multiple sclerosis: urgency and getting up twice at night, with a low post-void residual; Vitamin D deficiency. Strengths and supports remain part of the care plan. **S**

## Medication changes

- Started: Cholecalciferol (vitamin D3) 2000 units (50 mcg) oral capsule, one capsule daily **S**

## Plan

- Confirm and classify the diagnosis: MRI of the brain and the cervical and thoracic spine with gadolinium to the MAGNIMS-CMSC-NAIMS protocol, read against the 2017 McDonald criteria; exclude mimics with vitamin B12, TSH and HIV; request the records of the original evaluation. Guideline: Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria (Thompson AJ, et al.; PMID 29275977) (2017); 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis (Wattjes MP, et al.; PMID 34139157) (2021) **S**
- Neurology (multiple sclerosis) consultation to confirm and classify the disease and advise on disease-modifying therapy, its monitoring, vaccination, symptom care and MRI follow-up. Guideline: Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis (Rae-Grant A, et al.; PMID 29686116) (2018); Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria (Thompson AJ, et al.; PMID 29275977) (2017); 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis (Wattjes MP, et al.; PMID 34139157) (2021) **S**
- Screening before any disease-modifying therapy: hepatitis B surface antigen, core antibody and surface antibody; quantitative immunoglobulins; liver tests; blood count with lymphocytes; varicella and measles immunity; tuberculosis blood test; HIV and hepatitis C; JC virus antibody; and vaccines brought up to date, inactivated vaccines at least two weeks and live vaccines at least four weeks before the first dose. Guideline: Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis (Rae-Grant A, et al.; PMID 29686116) (2018); Practice guideline update summary: Vaccine-preventable infections and immunization in multiple sclerosis (Farez MF, et al.; PMID 31462584) (2019); Adult Immunization Schedule by Age (2026) **S**
- Relapse and pseudo-relapse plan: new or worsening symptoms lasting more than 24 hours without fever or heat mean a same-day call; check for urinary infection and fever first, because infection and heat can bring back old symptoms; written card for her bag. Guideline: Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis (Rae-Grant A, et al.; PMID 29686116) (2018); Multiple sclerosis in adults: management (NG220) (2022) **S**
- Mobility, spasticity and falls: physical therapy evaluation for gait, strengthening, stretching, balance and a home exercise program; review of walking aids, with forearm crutches or a rollator and a scooter for long distances when she wants them; home safety review; daily stretching. Guideline: Multiple sclerosis in adults: management (NG220) (2022); CMID: Clinical Monitoring Intelligence Database, osteoporosis and depression monographs (2026) **S**
- Bladder: post-void residual today, timed voiding, fluids earlier in the day, less caffeine, pelvic floor exercises, and a medicine if urgency persists; urine check for any burning, fever or sudden worsening. Guideline: Multiple sclerosis in adults: management (NG220) (2022) **S**
- Fatigue and heat sensitivity: energy conservation and pacing with an occupational therapy review, teaching sessions placed in the morning where she chooses, cooling garments, air conditioning, cool drinks, and aerobic exercise such as pool exercise in cool water. Guideline: Multiple sclerosis in adults: management (NG220) (2022) **S**
- Work: a letter to her employer, with her consent, describing her functional needs (an accessible teaching room near an elevator, a chair and lectern for lectures, reserved parking near her building, and flexibility for medical appointments) without naming the diagnosis; she decides what to disclose. Guideline: Accommodation and Compliance: Multiple Sclerosis (2026); Introduction to the Americans with Disabilities Act (2026) **S**
- Bone health: vitamin D3 with a recheck, calcium from food, weight-bearing exercise, fall prevention, and bone density at the preventive visit because of reduced mobility and earlier steroid courses. Guideline: Multiple sclerosis in adults: management (NG220) (2022); CMID: Clinical Monitoring Intelligence Database, osteoporosis and depression monographs (2026) **S**
- Mood and cognition: PHQ-9 at intake and every six months; ask about concentration and word-finding; counseling offered at any time. Guideline: Multiple sclerosis in adults: management (NG220) (2022); Depression and Suicide Risk in Adults: Screening (2023); CMID: Clinical Monitoring Intelligence Database, osteoporosis and depression monographs (2026) **S**
